Stocks · Health care · Pharmaceutical Preparations

Zentalis Pharmaceuticals, Inc.

ZNTL Clue Score26
United States Fiscal year ends December CIK 0001725160 Results filed 6 Aug 2026

What the insiders did No buying or selling

By person

13 insiders · 0 transactions
0.3×

Julie Eastland holds only 0.3 times base salary in stock. $276.97K of shares against $700.00K in salary for 2025.

Salary from the company's own proxy. The shares are what Julie Eastland last reported holding, valued at $3.50, the price Common Stock was last bought or sold at on the open market here, on 14 Aug 2026.

Insider
Role
Bought
Sold
Net
Holding
Worth
Change
Walters Group entity
10% owner
—
—
—
17,844,973
$62.46M
+153.1%
Matrix Capital Management Company, LP entity
10% owner
—
—
—
6,459,973
$22.61M
−53.7%
Andrea Paul
Chief Legal Officer
—
—
—
1,070,784
$3.75M
+614.0%
Mark Lackner
Chief Scientific Officer
—
—
—
512,856
$1.79M
+162.0%
Scott Dunseth Myers
Director
—
—
—
395,895
$1.39M
—
David Michael Johnson
Director
—
—
—
307,521
$1.08M
+59.5%
Jan Skvarka
Director
—
—
—
264,254
$924.89K
+195.1%
Luke Nathaniel Walker
Director
—
—
—
201,384
$704.84K
+177.8%
Enoch Kariuki
Director
—
—
—
194,465
$680.63K
+143.8%
Vincent Vultaggio
PAO and PFO
—
—
—
146,506
$512.77K
+332.7%
Shannon Campbell
Director
—
—
—
114,200
$399.70K
—
Julia Marie Eastland
CEO & President
—
—
—
79,133
$276.97K
—
Ingmar Bruns
Chief Medical Officer
—
—
—
43,059
$150.71K
—

No percentages here. These insiders hold more than one class of share between them, and the share count on file covers one of them rather than all. Dividing the two would compare different things.